ADC Therapeutics SA (ADCT) Revenue & Revenue Breakdown
ADC Therapeutics SA Revenue Highlights
Latest Revenue (Y)
$69.56M
Latest Revenue (Q)
$17.03M
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
ADC Therapeutics SA Revenue by Period
ADC Therapeutics SA Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $69.56M | -66.86% |
| 2022-12-31 | $209.91M | 518.89% |
| 2021-12-31 | $33.92M | 100.00% |
| 2020-12-31 | - | -100.00% |
| 2019-12-31 | $2.34M | 105.26% |
| 2018-12-31 | $1.14M | -36.77% |
| 2017-12-31 | $1.80M | - |
ADC Therapeutics SA generated $69.56M in revenue during NA 2023, up -66.86% compared to the previous quarter, and up 6101.58% compared to the same period a year ago.
ADC Therapeutics SA Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $17.03M | -5.67% |
| 2024-03-31 | $18.05M | 7.52% |
| 2023-12-31 | $16.79M | 15.85% |
| 2023-09-30 | $14.49M | -24.84% |
| 2023-06-30 | $19.28M | 1.53% |
| 2023-03-31 | $18.99M | -72.79% |
| 2022-12-31 | $69.80M | -8.55% |
| 2022-09-30 | $76.32M | 341.39% |
| 2022-06-30 | $17.29M | -62.81% |
| 2022-03-31 | $46.50M | 173.36% |
| 2021-12-31 | $17.01M | 29.38% |
| 2021-09-30 | $13.15M | 249.65% |
| 2021-06-30 | $3.76M | 100.00% |
| 2021-03-31 | - | -100.00% |
| 2020-12-31 | $51.90M | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | -100.00% |
| 2019-06-30 | $1.96M | 67.69% |
| 2019-03-31 | $1.17M | 354.37% |
| 2018-12-31 | $257.50K | - |
| 2018-09-30 | $257.50K | -17.60% |
| 2018-06-30 | $312.50K | - |
| 2018-03-31 | $312.50K | - |
ADC Therapeutics SA generated $17.03M in revenue during Q2 2024, up -5.67% compared to the previous quarter, and up 89.67% compared to the same period a year ago.
ADC Therapeutics SA Revenue Breakdown
ADC Therapeutics SA Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Product | $69.06M | - | - |
| Royalty Revenue | $498.00K | - | - |
| License Revenues | - | - | - |
| Contract Revenue | - | $135.00M | - |
| Product Revenue | - | $74.91M | $33.92M |
ADC Therapeutics SA's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (99.28%), and Royalty Revenue (0.72%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 |
|---|---|---|---|---|---|---|---|
| Product | $17.85M | - | - | - | - | - | - |
| Royalty Revenue | $205.00K | $373.00K | $86.00K | $39.00K | - | - | - |
| Product Revenue, Net | - | - | $19.20M | $18.95M | $21.32M | $17.29M | $16.50M |
| License Revenue | - | - | - | - | $55.00M | - | $30.00M |
ADC Therapeutics SA's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product (98.86%), and Royalty Revenue (1.14%).
ADC Therapeutics SA Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 |
|---|---|
| UNITED STATES | $69.06M |
| EMEA | $498.00K |
| JAPAN | - |
ADC Therapeutics SA's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (99.28%), and EMEA (0.72%).
Quarterly Revenue by Country
| Country | Mar 24 | Dec 23 | Jun 23 | Mar 23 |
|---|---|---|---|---|
| EMEA | $205.00K | $373.00K | $86.00K | $39.00K |
| UNITED STATES | $17.85M | $30.91M | $19.20M | $18.95M |
| JAPAN | - | - | - | - |
ADC Therapeutics SA's latest quarterly revenue breakdown by geography, as of Mar 24: UNITED STATES (98.86%), and EMEA (1.14%).
ADC Therapeutics SA Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RARE | Ultragenyx Pharmaceutical | $434.25M | $147.03M |
| ALEC | Alector | $97.06M | $15.89M |
| ARVN | Arvinas | $78.50M | $76.50M |
| ADCT | ADC Therapeutics SA | $69.56M | $17.03M |
| PTGX | Protagonist Therapeutics | $60.00M | $4.17M |
| AADI | Aadi Bioscience | $24.35M | $6.18M |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| RNA | Avidity Biosciences | $9.56M | $2.04M |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| GBIO | Generation Bio | $5.90M | $4.06M |
| CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
| IPSC | Century Therapeutics | $2.23M | $771.00K |
| FIXX | Q32 Bio | $1.16M | - |
| DSGN | Design Therapeutics | - | - |
| ALVR | AlloVir | - | - |
| ALXO | ALX Oncology | - | - |
| BDTX | Black Diamond Therapeutics | - | - |
| KURA | Kura Oncology | - | - |
| PASG | Passage Bio | - | - |
| AKRO | Akero Therapeutics | - | - |
ADCT Revenue FAQ
What is ADC Therapeutics SA’s yearly revenue?
ADC Therapeutics SA's yearly revenue for 2023 was $69.56M, representing a decrease of -66.86% compared to 2022. The company's yearly revenue for 2022 was $209.91M, representing an increase of 518.89% compared to 2021. ADCT's yearly revenue for 2021 was $33.92M, representing an increase of 100.00% compared to 2020.
What is ADC Therapeutics SA’s quarterly revenue?
ADC Therapeutics SA's quarterly revenue for Q2 2024 was $17.03M, a -5.67% decrease from the previous quarter (Q1 2024), and a -11.68% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $18.05M, a 7.52% increase from the previous quarter (Q4 2023), and a -4.94% decrease year-over-year (Q1 2023). ADCT's quarterly revenue for Q4 2023 was $16.79M, a 15.85% increase from the previous quarter (Q3 2023), and a -75.94% decrease year-over-year (Q4 2022).
What is ADC Therapeutics SA’s revenue growth rate?
ADC Therapeutics SA's revenue growth rate for the last 3 years (2021-2023) was 105.08%, and for the last 5 years (2019-2023) was 2872.56%.
What are ADC Therapeutics SA’s revenue streams?
ADC Therapeutics SA's revenue streams in c 23 are Product, and Royalty Revenue. Product generated $69.06M in revenue, accounting 99.28% of the company's total revenue Royalty Revenue generated $498K in revenue, accounting 0.72% of the company's total revenue
What is ADC Therapeutics SA’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of ADC Therapeutics SA was Product. This segment made a revenue of $69.06M, representing 99.28% of the company's total revenue.